Brinzolamide nanocrystal formulations for ophthalmic delivery: Reduction of elevated intraocular pressure in vivo

International Journal of Pharmaceutics

Volumn 467, Issue 1-2, 2014, Pages 34-41

  Tuomela, Annika ^a   Liu, Peng ^a   Puranen, Jooseppi ^b   Rönkkö, Seppo ^b   Laaksonen, Timo ^a   Kalesnykas, Giedrius ^b,c   Oksala, Olli ^d   Ilkka, Jukka ^e   Laru, Johanna ^f   Järvinen, Kristiina ^b   Hirvonen, Jouni ^a   Peltonen, Leena ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

^b UNIVERSITY OF EASTERN FINLAND   (Finland)

^c KUOPIO UNIVERSITY HOSPITAL   (Finland)

^d Santen Oy   (Finland)

^e Oy Medfiles Ltd   (Finland)

^f ORION CORPORATION   (Finland)

Author keywords

Brinzolamide; Glaucoma; Intraocular pressure; Nanocrystal suspension; Ophthalmic delivery

Indexed keywords

BRINZOLAMIDE; HYDROXYPROPYLMETHYLCELLULOSE; PHOSPHATE BUFFERED SALINE; POLOXAMER; POLYSORBATE 80; CARBONATE DEHYDRATASE INHIBITOR; EXCIPIENT; NANOPARTICLE; POLYSORBATE; SULFONAMIDE; THIAZINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL VIABILITY; CONTROLLED STUDY; CORNEA EPITHELIUM; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG FORMULATION; DRUG SOLUBILITY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; LIMIT OF DETECTION; MALE; NONHUMAN; OCULAR DRUG DELIVERY SYSTEM; PARTICLE SIZE; PH; PRIORITY JOURNAL; RAT; SOLID STATE; SUSPENSION; TONOMETER; TOPICAL TREATMENT; ANIMAL; CELL LINE; CELL SURVIVAL; CHEMISTRY; COMPARATIVE STUDY; DIFFERENTIAL SCANNING CALORIMETRY; DISEASE MODEL; DRUG EFFECTS; ENZYMOLOGY; GLAUCOMA; INTRAOCULAR DRUG ADMINISTRATION; MEDICINAL CHEMISTRY; NANOTECHNOLOGY; PATHOLOGY; PATHOPHYSIOLOGY; PHARMACEUTICS; PROCEDURES; SCANNING ELECTRON MICROSCOPY; SOLUBILITY; SURFACE PROPERTY; TIME; TOXICITY; WISTAR RAT;

ADMINISTRATION, OPHTHALMIC; ANIMALS; CALORIMETRY, DIFFERENTIAL SCANNING; CARBONIC ANHYDRASE INHIBITORS; CELL LINE; CELL SURVIVAL; CHEMISTRY, PHARMACEUTICAL; DISEASE MODELS, ANIMAL; EPITHELIUM, CORNEAL; EXCIPIENTS; GLAUCOMA; HUMANS; HYPROMELLOSE DERIVATIVES; INTRAOCULAR PRESSURE; MALE; MICROSCOPY, ELECTRON, SCANNING; NANOPARTICLES; NANOTECHNOLOGY; PARTICLE SIZE; POLYSORBATES; RATS, WISTAR; SOLUBILITY; SULFONAMIDES; SURFACE PROPERTIES; TECHNOLOGY, PHARMACEUTICAL; THIAZINES; TIME FACTORS;

EID: 84898755869     PISSN: 03785173     EISSN: 18733476     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2014.03.048     Document Type: Article

References (51)

1. Alcon Laboratories, I., 2004. Product Information, CYCLOGYL® Ophthalmic Solution, 2004, 2014.
2. H.S. Ali, P. York, A.M. Ali, and N. Blagden Hydrocortisone nanosuspensions for ophthalmic delivery: A comparative study between microfluidic nanoprecipitation and wet milling Journal of Controlled Release 149 2011 175 181 10.1016/j.jconrel.2010.10.007
3. Allison, J., Elan sues Alcon over eye treatment Azopt., http://www.law360.com/articles/84323/elan-sues-alcon-over-eye-treatment-azopt.
4. K. Araki-Sasaki, Y. Ohashi, T. Sasabe, K. Hayashi, H. Watanabe, Y. Tano, and H. Handa An SV40-immortalized human corneal epithelial cell line and its characterization Investigative Ophthalmology & Visual Science 36 1995 614 621
5. T.J. Bunch, B. Tian, J.L. Seeman, B.T. Gabelt, T.L. Lin, and P.L. Kaufman Effect of daily prolonged ketamine anesthesia on intraocular pressure in monkeys Current Eye Research 33 2008 946 953 10.1080/02713680802447121
6. P. Colombo Swelling-controlled release in hydrogel matrices for oral route Advanced Drug Delivery Reviews 11 1993 37 57 10.1016/0169-409X(93)90026-Z
7. L. DeSantis Preclinical overview of brinzolamide Survey of Ophthalmology 44 2000 S119 S129 10.1016/S0039-6257(99)00108-3 Suppl. 2
8. S. Dey, and A.K. Mitra Transporters and receptors in ocular drug delivery: opportunities and challenges Expert Opinion on Drug Delivery 2 2005 201 204 10.1517/17425247.2.2.201
9. C. Ding, P. Wang, and N. Tian Effect of general anesthetics on IOP in elevated IOP mouse model Experimental Eye Research 93 2011 512 520 10.1016/j.exer.2011.03.016
10. D. Douroumis, and A. Fahr Stable carbamazepine colloidal systems using the cosolvent technique European Journal of Pharmaceutical Sciences 30 2007 367 374 10.1016/j.ejps.2006.12.003
11. S. Duvvuri, S. Majumdar, and A.K. Mitra Drug delivery to the retina: challenges and opportunities Expert Opinion on Biological Therapy 3 2003 45 56 10.1517/14712598.3.1.45
12. S. El-Sousi, A. Nácher, C. Mura, A. Catalán-Latorre, V. Merino, M. Merino-Sanjuán, and O. Díez-Sales Hydroxypropylmethylcellulose films for the ophthalmic delivery of diclofenac sodium Journal of Pharmacy and Pharmacology 65 2013 193 200 10.1111/j.2042-7158. 2012.01587.x
13. European Medicines Agancy - EMEA, 2008. Assessment Report for Azopt., http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Assessment-Report- Variation/human/000267/WC500030365.pdf
14. European Medicines Agancy - EMEA, 2004. Product Information: Azopt., http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Scientific-Discussion/ human/000267/WC500030362.pdf
15. FDA US Food and Drug Administration: Inactive Ingredients for Approved Drug Products 2013
16. D. Geroski, and H. Edelhauser Drug delivery for posterior segment eye disease Investigative Ophthalmology & Visual Science 41 2000 961 964
17. M. Gibson Ophthalmic dosage forms M. Gibson, Pharmaceutical Preformulation and Formulation, A Practical Guide from Candidate Drug Selection to Commercial Dosage Form 2nd ed. 2009 Informa Healthcare USA, Inc. New York, London 431 455
18. M.O. Gordon, J.A. Beiser, J.D. Brandt, D.K. Heuer, E.J. Higginbotham, C.A. Johnson, J.L. Keltner, J.P. Miller, R.K. Parrish 2nd, M.R. Wilson, and M.A. Kass The Ocular Hypertension Treatment Study: baseline factors that predict the onset of primary open-angle glaucoma Archives of Ophthalmology 120 2002 714 720 discussion 829-30
19. R. Hall, G. Havner, J. Baker, G. Stafford, W. Schneider, W. Lin, J. May, M. Curtis, C. Struble, B. McCue, D. Jasheway, and D. McGee Brinzolamide H.G. Brittain, Analytical Profiles of Drug Substances and Excipient 26 1999 47 96
20. H. Hui, and J.R. Robinson Effect of particle dissolution rate on ocular drug bioavailability Journal of Pharmaceutical Sciences 75 1986 280 287 10.1002/jps.2600750316
21. Inoue, J., Shah, T., 2011. Ophthalmic composition US20110275617 A1, 10. November.
22. K. Järvinen, T. Järvinen, D. Thompson, and V. Stella The effect of a modified beta-cyclodextrin, SBE4-beta-CD, on the aqueous stability and ocular absorption of pilocarpine Current Eye Research 13 1994 897 905
23. L. Jia, W.O. Cepurna, E.C. Johnson, and J.C. Morrison Effect of general anesthetics on IOP in rats with experimental aqueous outflow obstruction Investigative Ophthalmology & Visual Science 41 2000 3415 3419
24. G. Kalesnykas, M. Niittykoski, J. Rantala, R. Miettinen, A. Salminen, K. Kaarniranta, and H. Uusitalo The expression of heat shock protein 27 in retinal ganglion and glial cells in a rat glaucoma model Neuroscience 150 2007 692 704 10.1016/j.neuroscience.2007.09.078
25. M.A. Kassem, A.A. Abdel Rahman, M.M. Ghorab, M.B. Ahmed, and R.M. Khalil Nanosuspension as an ophthalmic delivery system for certain glucocorticoid drugs International Journal of Pharmaceutics 340 2007 126 133 10.1016/j.ijpharm.2007. 03.011
26. I.P. Kaur, and M. Kanwar Ocular preparations: the formulation approach Drug Development and Industrial Pharmacy 28 2002 473 493 10.1081/DDC-120003445
27. I.P. Kaur, and R. Smitha Penetration enhancers and ocular bioadhesives: two new avenues for ophthalmic drug delivery Drug Development and Industrial Pharmacy 28 2002 353 369 10.1081/DDC-120002997
28. O. Kayser, A. Lemke, and N. Hernandez-Trejo The impact of nanobiotechnology on the development of new drug delivery systems Current Pharmaceutical Biotechnology 6 2005 3 5
29. O. Kayser, C. Olbrich, V. Yardley, A.F. Kiderlen, and S.L. Croft Formulation of amphotericin B as nanosuspension for oral administration International Journal of Pharmaceutics 254 2003 73 75 10.1016/S0378-5173(02) 00686-5
30. J.C. Keister, E.R. Cooper, P.J. Missel, J.C. Lang, and D.F. Hager Limits on optimizing ocular drug delivery Journal of Pharmaceutical Sciences 80 1991 50 53
31. S.B. Koevary Pharmacokinetics of topical ocular drug delivery: potential uses for the treatment of diseases of the posterior segment and beyond Current Drug Metabolism 4 2003 213 222
32. M. Larsson, A. Viridén, M. Stading, and A. Larsson The influence of HPMC substitution pattern on solid-state properties Carbohydrate Polymers 82 2010 1074 1081 10.1016/j.carbpol.2010.06.030
33. P. Liu, X. Rong, J. Laru, van Veen, B. Kiesvaara, J. Hirvonen, J. Laaksonen, T. Peltonen, and L Nanosuspensions of poorly soluble drugs: Preparation and development by wet milling International Journal of Pharmaceutics 411 2011 215 222 10.1016/j.ijpharm.2011.03.050
34. A. Ludwig The use of mucoadhesive polymers in ocular drug delivery Advanced Drug Delivery Reviews 57 2005 1595 1639 10.1016/j.addr.2005.07.005
35. R.H. Müller, C. Jacobs, and O. Kayser Nanosuspensions as particulate drug formulations in therapy: Rationale for development and what we can expect for the future Advanced Drug Delivery Reviews 47 2001 3 19 10.1016/S0169- 409X(00)00118-6
36. R. Pignatello, C. Bucolo, P. Ferrara, A. Maltese, A. Puleo, and G. Puglisi Eudragit RS100 nanosuspensions for the ophthalmic controlled delivery of ibuprofen European Journal of Pharmaceutical Sciences 16 2002 53 61
37. H.A. Quigley Glaucoma Lancet 2011 10.1016/S0140-6736(10)61423-7
38. E. Reverchon, G. Lamberti, and A. Antonacci Supercritical fluid assisted production of HPMC composite microparticles The Journal of Supercritical Fluids 46 2008 185 196 10.1016/j.supflu.2008.04.010
39. S.K. Sahoo, F. Dilnawaz, and S. Krishnakumar Nanotechnology in ocular drug delivery Drug Discovery Today 13 2008 144 151 10.1016/j.drudis.2007.10.021
40. Y. Sakata, and H. Yamaguchi Effects of calcium salts on thermal characteristics of hydroxypropyl methylcellulose films Journal of Non-Crystalline Solids 357 2011 1279 1284 10.1016/j.jnoncrysol.2010.12.031
41. Scheve, S., Riddle, R., Siebman, C., Biotech & Pharma Patent Law: Civil action no 4.09-CV-32, demand for jury trial: Elan Pharma International (Plaintiff) vs. Alcon Laboratories Inc. and Alcon Manufacturing, LTD., http://patentdocs.typepad.com/files/elan-v-alcon.pdf
42. S. Sepassi, D.J. Goodwin, A.F. Drake, S. Holland, G. Leonard, L. Martini, and M.J. Lawrence Effect of polymer molecular weight on the production of drug nanoparticles Journal of Pharmaceutical Sciences 96 2007 2655 2666 10.1002/jps.20979
43. J. Siepmann, and N.A. Peppas Modeling of drug release from delivery systems based on hydroxypropyl methylcellulose (HPMC) Advances in Drug Delivery Reviews 48 2001 139 157 10.1016/S0169-409X(01)00112-0
44. P. Tangri, and S. Khurana Basics of ocular drug delivery International Journal of Research in Pharmaceutical and Biomedical Sciences 4 2011 1541 1552
45. R. Thakur, and M. Kashiv Modern delivery systems for ocular drug formulations: a comparative overview w. r. t conventional dosage form International Journal of Research in Pharmaceutical and Biomedical Sciences 2 2011 8 18
46. I. Toda, N. Shinozaki, and K. Tsubota Hydroxypropyl methylcellulose for the treatment of severe dry eye associated with Sjogren's syndrome Cornea 15 1996 120 128
47. E. Toropainen, V.P. Ranta, K.S. Vellonen, J. Palmgren, A. Talvitie, M. Laavola, P. Suhonen, K.M. Hamalainen, S. Auriola, and A. Urtti Paracellular and passive transcellular permeability in immortalized human corneal epithelial cell culture model European Journal of Pharmaceutical Sciences 20 2003 99 106
48. A. Urtti, J.D. Pipkin, G. Rork, T. Sendo, U. Finne, and A.J. Repta Controlled drug delivery devices for experimental ocular studies with timolol 2. Ocular and systemic absorption in rabbits International Journal of Pharmaceutics 61 1990 241 249 10.1016/0378-5173(90)90215-P
49. W. Wu, J. Li, L. Wu, B. Wang, Z. Wang, Q. Xu, and H. Xin Ophthalmic delivery of brinzolamide by liquid crystalline nanoparticles: in vitro and in vivo evaluation AAPS PharmSciTech 14 2013 1063 1071 10.1208/s12249-013-9997-2
50. D. Xia, P. Quan, H. Piao, H. Piao, S. Sun, Y. Yin, and F. Cui Preparation of stable nitrendipine nanosuspensions using the precipitation-ultrasonication method for enhancement of dissolution and oral bioavailability European Journal of Pharmaceutical Sciences 40 2010 325 334 10.1016/j.ejps.2010.04.006
51. Y. Xu, X. Liu, R. Lian, S. Zheng, Z. Yin, Y. Lu, and W. Wu Enhanced dissolution and oral bioavailability of aripiprazole nanosuspensions prepared by nanoprecipitation/homogenization based on acid-base neutralization International Journal of Pharmaceutics 438 2012 287 295 10.1016/j.ijpharm.2012. 09.020